221124 Interim results FY23H1 App 2 amended

Results for announcement to the market
AFT Pharmaceuticals Limited
Reporting Period 6 months to September 30 2022
Previous Reporting Period 6 months to September 30 2021
Currency NZ$
Amount (000s) Percentage change
Revenue from continuing
operations
$65,750 Up 18%
Total Revenue $65,750 Up 18%
Net operating profit/(loss) from
continuing operations
$3,457 Down 37%
Total operating net profit/(loss) $3,457 Down 37%
Net profit/(loss) after tax from
continuing operations
$1,452 Down 66%
Total Net profit/(loss) after tax $1,452 Down 66%
Interim/Final Dividend
Quoted Equity Securities:
Amount per Quoted Equity
Security
No dividends have been paid on ordinary shares and it is
currently not proposed to pay dividends.
Imputed amount per Quoted
Equity Security
Not Applicable
Record Date Not Applicable
Dividend Payment Date Not Applicable
Unquoted Equity Securities:
Amount per Unquoted
Redeemable Preference Share
Not Applicable
Imputed Amount per Unquoted
Redeemable Preference Share
Not Applicable
Record Dates Not Applicable
Dividend Payment Dates Not Applicable
Current period Prior comparable period
Net tangible assets per Quoted
Equity Security
$0.15 $0.05
A brief explanation of any of the
figures above necessary to
enable the figures to be
understood
Accompanying this announcement are the Group’s unaudited
consolidated financial statements for the six months ended
30 September 2022. These financial statements and the half
year results commentary dated 24 November 2022 provide
the balance of information requirements in accordance with
NZX Listing Rule 3.5 and Appendix 2.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969

Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals
Limited confirms that it continues to comply with the rules of
its home exchange (NZX Main Board).

Authority for this announcement
Name of person

authorised to
make this announcement
Malcolm Tubby
Contact person for this
announcement
Malcolm Tubby, Chief Financial Officer,
AFT Pharmaceuticals Ltd
Contact phone number +64 9 488 0232
Contact email address malcolm@aftpharm.com
Date of release through MAP

24 November 2022

Unaudited financial statements accompany this announcement.